4//SEC Filing
Pierce David A 4
Accession 0001225208-22-003299
CIK 0000885725other
Filed
Feb 23, 7:00 PM ET
Accepted
Feb 24, 4:21 PM ET
Size
9.0 KB
Accession
0001225208-22-003299
Insider Transaction Report
Form 4
Pierce David A
SVP and President, Endoscopy
Transactions
- Sale
Common Stock
2022-02-22$42.55/sh−1,884$80,164→ 1,761 total - Sale
Common Stock
2022-02-23$43.28/sh−1,761$76,216→ 0 total - Award
Performance Share Units
2022-02-22+17,439→ 17,439 totalFrom: 2023-12-31Exp: 2023-12-31→ Common Stock (17,439 underlying)
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.
- [F2]Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.
- [F3]On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023.
Documents
Issuer
BOSTON SCIENTIFIC CORP
CIK 0000885725
Entity typeother
Related Parties
1- filerCIK 0001529751
Filing Metadata
- Form type
- 4
- Filed
- Feb 23, 7:00 PM ET
- Accepted
- Feb 24, 4:21 PM ET
- Size
- 9.0 KB